Water for Injections Freeflex New Zealand - English - Medsafe (Medicines Safety Authority)

water for injections freeflex

fresenius kabi new zealand limited - water for injection 100% - solution for injection - active: water for injection 100% - water for injections is used to dissolve or dilute substances or preparations for parenteral administration. water for injections may also be used as an irrigating solution for small wounds or during minor surgical procedures.

Volulyte 6% Solution for Infusion Malta - English - Medicines Authority

volulyte 6% solution for infusion

fresenius kabi limited - poly(o-2-hydroxyethyl)starch; potassium chloride; magnesium chloride hexahydrate; sodium acetate trihydrate; sodium chloride - solution for infusion - poly(o-2-hydroxyethyl)starch 60 g; potassium chloride 0.3 g; magnesium chloride hexahydrate 0.3 g; sodium acetate trihydrate 4.63 g; sodium chloride 6.02 g - blood substitutes and perfusion solutions

IRINOTECAN KABI irinotecan hydrochloride trihydrate 500mg/25mL concentrated injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

irinotecan kabi irinotecan hydrochloride trihydrate 500mg/25ml concentrated injection vial

fresenius kabi australia pty ltd - irinotecan hydrochloride trihydrate, quantity: 500 mg - injection, concentrated - excipient ingredients: sorbitol; lactic acid; sodium hydroxide; water for injections - irinotecan injection is indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

IRINOTECAN KABI irinotecan hydrochloride trihydrate 300mg/15mL concentrated injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

irinotecan kabi irinotecan hydrochloride trihydrate 300mg/15ml concentrated injection vial

fresenius kabi australia pty ltd - irinotecan hydrochloride trihydrate, quantity: 300 mg - injection, concentrated - excipient ingredients: sorbitol; lactic acid; sodium hydroxide; water for injections - irinotecan injection is indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

VOLULYTE 6% Australia - English - Department of Health (Therapeutic Goods Administration)

volulyte 6%

fresenius kabi australia pty ltd - hydroxyethyl starch 130/0.4, quantity: 60 g/l; sodium chloride, quantity: 6.02 g/l; potassium chloride, quantity: 0.3 g/l; magnesium chloride hexahydrate, quantity: 0.3 g/l; sodium acetate trihydrate, quantity: 4.63 g/l - injection, intravenous infusion - excipient ingredients: water for injections; sodium hydroxide; hydrochloric acid - treatment of hypovolaemia due to acute blood loss when crystalloids alone are not considered sufficient. the use of volulyte is not a substitute for the appropriate use of packed red blood cells or fresh frozen plasma.

IRINOTECAN KABI irinotecan hydrochloride trihydrate 40 mg/2 mL concentrated injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

irinotecan kabi irinotecan hydrochloride trihydrate 40 mg/2 ml concentrated injection vial

fresenius kabi australia pty ltd - irinotecan hydrochloride trihydrate, quantity: 40 mg - injection, concentrated - excipient ingredients: lactic acid; sorbitol; sodium hydroxide; water for injections - irinotecan injection is indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

IRINOTECAN KABI irinotecan hydrochloride trihydrate 100 mg/5 mL concentrated injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

irinotecan kabi irinotecan hydrochloride trihydrate 100 mg/5 ml concentrated injection vial

fresenius kabi australia pty ltd - irinotecan hydrochloride trihydrate, quantity: 100 mg - injection, concentrated - excipient ingredients: water for injections; lactic acid; sodium hydroxide; sorbitol - irinotecan injection is indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

VOLULYTE 6% Australia - English - Department of Health (Therapeutic Goods Administration)

volulyte 6%

fresenius kabi australia pty ltd - potassium chloride, quantity: 0.3 g/l; sodium chloride, quantity: 6.02 g/l; hydroxyethyl starch 130/0.4, quantity: 60 g/l; magnesium chloride hexahydrate, quantity: 0.3 g/l; sodium acetate trihydrate, quantity: 4.63 g/l - injection, intravenous infusion - excipient ingredients: water for injections; sodium hydroxide; hydrochloric acid - treatment of hypovolaemia due to acute blood loss when crystalloids alone are not considered sufficient. the use of volulyte is not a substitute for the appropriate use of packed red blood cells or fresh frozen plasma.

Hartmann’s Solution for Infusion, PVC bag Ireland - English - HPRA (Health Products Regulatory Authority)

hartmann’s solution for infusion, pvc bag

fresenius kabi limited - sodium chloride; potassium chloride; calcium chloride dihydrate ; sodium lactate solution 50% - solution for infusion - %v/v - solutions affecting the electrolyte balance; electrolytes

Hartmann’s Solution for Infusion, PSEB bag Ireland - English - HPRA (Health Products Regulatory Authority)

hartmann’s solution for infusion, pseb bag

fresenius kabi limited - sodium chloride; potassium chloride; calcium chloride dihydrate ; sodium lactate solution 50% - solution for infusion - %v/v - solutions affecting the electrolyte balance; electrolytes